Evidence map›Paper›PMID 21857991›Full record

ArticlePloS one2011

ATR-p53 restricts homologous recombination in response to replicative stress but does not limit DNA interstrand crosslink repair in lung cancer cells.

Bianca M Sirbu, Sarah J Lachmayer, Verena Wülfing, Lara M Marten, Katie E Clarkson, Linda W Lee, Liliana Gheorghiu, Lee Zou, Simon N Powell, Jochen Dahm-Daphi and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. p53 in the DNA-Damage-Repair Process.Cold Spring Harbor perspectives in medicine · 2016
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Bianca M SirbuLaboratory of Cellular and Molecular Radiation Oncology, Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts, United States of America.
Sarah J Lachmayer
Verena Wülfing
Lara M Marten
Katie E Clarkson
Linda W Lee
Liliana Gheorghiu
Lee Zou
Simon N Powell
Jochen Dahm-Daphi
Henning Willers
Massachusetts General Hospital · USCenter for Cancer Research · USHarvard University · USMemorial Sloan Kettering Cancer Center · USPhilipps University of Marburg · DE

Funding

Translational studies of Hsp90 inhibitors in NSCLCP50CA090578 · NCI · DANA-FARBER CANCER INST · PI YEAP, BEOW Y · 2008 to 2012
$11.4M
Regulation of the ATR Checkpoint Kinase by DNA DamageR01GM076388 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI ZOU, LEE · 2006 to 2018
$4.3M
DNA REPAIR--ROLE OF THE P53 TUMOR SUPPRESSOR PROTEINR01CA058985 · NCI · WASHINGTON UNIVERSITY · PI POWELL, SIMON N. · 1992 to 2010
$2.8M
PROTON THERAPY RESEARCH AND TREATMENT CENTERC06CA059267 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI GOITEIN, MICHAEL · 1992 to 1995
–
NCI NIH HHS C06 CA059267NCI NIH HHS P50 CA090578NCI NIH HHS R01 CA058985NCI NIH HHS R01 CA58985NIGMS NIH HHS R01 GM076388
6 · The paper itself

Abstract

Homologous recombination (HR) is required for the restart of collapsed DNA replication forks and error-free repair of DNA double-strand breaks (DSB). However, unscheduled or hyperactive HR may lead to genomic instability and promote cancer development. The cellular factors that restrict HR processes in mammalian cells are only beginning to be elucidated. The tumor suppressor p53 has been implicated in the suppression of HR though it has remained unclear why p53, as the guardian of the genome, would impair an error-free repair process. Here, we show for the first time that p53 downregulates foci formation of the RAD51 recombinase in response to replicative stress in H1299 lung cancer cells in a manner that is independent of its role as a transcription factor. We find that this downregulation of HR is not only completely dependent on the binding site of p53 with replication protein A but also the ATR/ATM serine 15 phosphorylation site. Genetic analysis suggests that ATR but not ATM kinase modulates p53's function in HR. The suppression of HR by p53 can be bypassed under experimental conditions that cause DSB either directly or indirectly, in line with p53's role as a guardian of the genome. As a result, transactivation-inactive p53 does not compromise the resistance of H1299 cells to the interstrand crosslinking agent mitomycin C. Altogether, our data support a model in which p53 plays an anti-recombinogenic role in the ATR-dependent mammalian replication checkpoint but does not impair a cell's ability to use HR for the removal of DSB induced by cytotoxic agents.

Indexed as

DNA RepairHomologous RecombinationAnimalsAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsCell Line, TumorCells, CulturedCell SurvivalCross-Linking ReagentsDNA Breaks, Double-StrandedDNA DamageDNA ReplicationFlow CytometryHumansLung NeoplasmsMiceAtaxia Telangiectasia Mutated ProteinsATR protein, humanCell Cycle ProteinsCross-Linking ReagentsMitomycinProtein Serine-Threonine KinasesRad51 RecombinaseThymidineTumor Suppressor Protein p53

Identifiers

PMID21857991
PMCPMC3155521
OpenAlexW2088309735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.